Pausing breast cancer treatment for pregnancy appears safe
Young women diagnosed with breast cancer often must delay pregnancy for years while they take hormone-blocking pills.
A reassuring new study finds they can take a two-year break from these drugs to get pregnant without raising their short-term risk of the cancer coming back.
“This is really good news for young women and their doctors and their families,” said Dr. Ann Partridge of Dana-Farber Cancer Institute in Boston, who led the study. Results were being discussed Thursday at the San Antonio Breast Cancer Symposium.
Though more common in older women, breast cancer is increasingly diagnosed during childbearing years for reasons that aren’t clear.
For patients whose cancers are fueled by hormones, treatment involves surgery, then spending five to 10 years taking either a hormone-blocking drug that can cause birth defects or newer drugs called aromatase inhibitors and a monthly shot to shut down the ovaries.
Partridge estimates 6,000 U.S. women a year who want to get pregnant must take hormone-blocking drugs.
“They don’t want to hear from breast cancer again, but they also don’t want to put their lives on hold,” she said.
Breast cancer will strike 1 in 8 women in her lifetime.
The study followed 516 women after surgery for early-stage cancer. All then spent at least 18 months taking hormone-blocking drugs. The women stopped hormone blockers for up to two years to get pregnant, deliver and breastfeed. Then they restarted the therapy.
After three years, about 9% saw cancer come back. That was similar to the rate seen in similar women from a separate study who stayed on hormone-blocking therapy. There were nine deaths, “below expected rates for this population,” Partridge said.
More than 300 babies were born to women in the study. Among them was Brayden, now 4, the son of Amy Bianchi.
“He’s perfect in every way,” Bianchi said. “I couldn’t imagine my life without him. We couldn’t imagine our family without him.”
Bianchi felt a lump, which turned out to be breast cancer, when her firstborn, Mia, was 18 months old. Doctors advised against another pregnancy, but she learned of the research and signed up.
“If I had listened to the first few doctors or oncologists that I spoke with, I would have lost all my hope,” said Bianchi, 42, of Niskayuna, N.Y. “I would have very quickly accepted that I would never have the family that I had envisioned.”
She was able to breastfeed her son for six months before resuming hormone-blocking therapy, which she’ll continue until 2026.
A pill has been shown to help keep certain early-stage, hard-to-treat breast cancers at bay after initial treatment.
Researchers will follow Bianchi and the other study participants and report on the longer-term safety.
“Will we see a difference at 10 years?” asked Dr. Hope Rugo of UC San Francisco, who was not involved in the study. “For the moment, this is incredibly encouraging data. It should give practitioners and patients confidence” as they discuss ways to benefit from cancer therapy while starting a family, Rugo said.
